What is Sera Prognostics Inc (SERA) stock price today?

Sera Prognostics Inc (SERA) currently trades at $1.99 per share. The stock has a market capitalization of $77.93M and a P/E ratio of —x.

Is SERA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Sera Prognostics Inc has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -5.52.

What is Sera Prognostics Inc's revenue and earnings?

Sera Prognostics Inc has trailing twelve-month (TTM) revenue of $81000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-0.67.

Is Sera Prognostics Inc financially healthy?

Sera Prognostics Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -5.52 places it in the distress.

SERA

Sera Prognostics Inc

NASDAQ: SERA · HEALTHCARE · MEDICAL DEVICES

$1.99

+0.51% today

Updated 2026-04-29

Market cap

$77.93M

P/E ratio

—

P/S ratio

962.05x

EPS (TTM)

$-0.67

Dividend yield

—

52W range

$1 – $4

Volume

0.1M

Market cap

$77.93M

P/E ratio

—

P/S ratio

962.05x

EPS (TTM)

$-0.67

Dividend yield

—

52W range

$1 – $4

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.5

Quality

C+

2.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-5.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$5.00

+151.26%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.03x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -5.52 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-6.45M

- Revenue declining -58.30% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$268000.00	$306000.00	$77000.00	$81000.00	$81000.00
Net income	$-44.19M	$-36.24M	$-32.90M	$-31.93M	$-7.88M
EPS	—	—	—	—	$-0.67
Free cash flow	$-35.40M	$-27.32M	$-15.29M	$-26.35M	$-6.45M
Profit margin	-16,487.31%	-11,843.79%	-42,724.68%	-39,417.28%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SERA	$77.93M	25	2.7	2.5	5.0	5.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Sera Prognostics Inc trades at $1.99. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -5.52, it sits in the distress. TTM revenue stands at $81000.00.

Frequently asked questions

What is Sera Prognostics Inc's stock price?

Sera Prognostics Inc (SERA) trades at $1.99.

Is Sera Prognostics Inc overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell).

What is the price target of Sera Prognostics Inc (SERA)?

The analyst target price is $5.00, representing +151.3% upside from the current price of $1.99.

What is Sera Prognostics Inc's revenue?

TTM revenue is $81000.00.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-5.52 — distress.

Company info

SectorHEALTHCARE

IndustryMEDICAL DEVICES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.sera.com

Quick metrics

P/S ratio962.05x

ROE-51.80%

Beta1.06

50D MA$2.10

200D MA$2.82

Shares out0.04B

Float0.03B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

SERA vs LLY →SERA vs JNJ →SERA vs ABBV →Stock screener →